Pemvidutide vs HM15211

Head-to-head comparison of Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) and HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyPemvidutideHM15211
CategoryWeight ManagementWeight Management
Full NamePemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonistHM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist
Molecular WeightN/AN/A
Half-LifeApproximately 1 weekApproximately 1 week
Amino AcidsN/AN/A
Typical DoseTrial-dependent; once-weekly SC titrationInvestigational; no established human dose
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count1812
Research StatusClinicalClinical

Pemvidutide Benefits

  • appetite suppression
  • body-weight reduction
  • improved liver-fat markers
  • better glycemic control

HM15211 Benefits

  • appetite suppression
  • greater fat oxidation
  • weight loss
  • improved metabolic markers

Pemvidutide Dosing

once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose

HM15211 Dosing

once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose

Pemvidutide Side Effects

  • nausea
  • vomiting
  • diarrhea

HM15211 Side Effects

  • nausea
  • vomiting
  • reduced appetite

Research Overview

Pemvidutide

Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.

HM15211

Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Pemvidutide stacks with:

metformintopiramate

HM15211 stacks with:

metformintopiramate
glp1glucagondual-agonistobesitymashgiptriagonist